Searchable abstracts of presentations at key conferences in endocrinology

ea0014s4.1 | Gastroenteropancreatic endocrine tumors | ECE2007

Pathological classification of GEP neuroendocrine tumors

Papotti Mauro , Righi Luisella , Volante Marco

In the gastroentero-pancreatic tract, a spectrum of neuroendocrine tumors (NET) exists, including low grade tumors (carcinoid), intermediate grade malignant carcinoid, and high grade poorly differentiated carcinomas of the small and large cell types. In year 2000, the WHO presented a classification scheme for all NETs, but mostly applied to gastroentero-pancreatic tumors. This term carcinoid was replaced by (neuro)endocrine tumor, malignant carcinoid by well differentiated (ne...

ea0032p15 | Adrenal cortex | ECE2013

In vivo and in vitro evidence supporting SSTR/mTOR pathway targeting in adrenocortical cancer

Germano Antonina , Rapa Ida , Duregon Eleonora , Votta Arianna , Ardito Arianna , Volante Marco , Papotti Mauro , Terzolo Massimo

Objective: In vitro data suggest that somatostatin receptors (SSTR) and mTOR pathways might represent reasonable targets for novel therapies, since are involved in growth of adrenocortical carcinoma (ACC). However, in vitro analysis of combination treatments, targeting both mTOR and SSTR as compared to mitotane, and detailed tissue typing mTOR/SSTR pathway are poorly explored in ACC.Methods: This study was designed to characterize the t...

ea0081oc6.5 | Oral Communications 6: Endocrine-Related Cancer | ECE2022

Antagonist of growth hormone-releasing hormone (GHRH) potentiates the antitumor effect of chemotherapy in human malignant pleural mesothelioma

Gesmundo Iacopo , Vitale Nicoletta , Orlando Giulia , Bertoldo Alessia , Papotti Mauro , Deaglio Silvia , Ghigo Ezio , Schally Andrew V , Granata Riccarda

Human malignant pleural mesothelioma (MPM) is a rare but aggressive neoplasm, arising from pleural mesothelial cells, generally due exposure to asbestos. Of note, different growth factors and their receptors are involved in the pathogenesis of MPM and resistance to therapy. Chemotherapy with cisplatin (cis) and antifolates, like pemetrexed (PEM), is the first-line treatment for inoperable MPM. Growth hormone-releasing hormone (GHRH), besides stimulating GH secretion in the ant...

ea0052p02 | (1) | UKINETS2017

Validation of a blood biomarker test for the diagnosis and management of bronchopulmonary neuroendocrine tumors

Modlin Irvin , Kidd Mark , Lewczuk Anna , Chung Kjung-Min , Kolasinska-Cwikla Agnieska , Cwikla Jaroslaw , Lowczak Anna , Doboszynska Anna , Tesselaar Margot , Buikhuisen Wieneke , Malczewska Anna , Kos-Kudla Beata , Roffinella Matteo , Filosso Pier Luigi , Korse Tiny , Papotti Mauro , Bodei Lisa , Drozdov Ignat

Background: There is currently no effective blood biomarker for lung neuroendocrine neoplasia diagnosis and management. We describe the clinical utility of a 51 neuroendocrine-specific gene expression set in blood to diagnose bronchopulmonary neuroendocrine tumors (BPNETs) and define their clinical status.Methods: The discovery set included BPNETs (n=154) and controls (n=90), randomly assigned (1:1) to a test and validation set. Specifi...

ea0081p9 | Adrenal and Cardiovascular Endocrinology | ECE2022

Development and internal validation of a predictive model for the estimation of pheochromocytoma recurrence risk after radical surgery

Lopez Chiara , Parasiliti Caprino Mirko , Bioletto Fabio , Bollati Martina , Maletta Francesca , Caputo Marina , Gasco Valentina , La Grotta Antonio , Limone Paolo , Borretta Giorgio , Volante Marco , Papotti Mauro , Terzolo Massimo , Morino Mario , Pasini Barbara , Veglio Franco , Ghigo Ezio , Arvat Emanuela , Maccario Mauro

Objective: Various features have been identified as predictors of relapse after complete resection of pheochromocytoma, but a comprehensive multivariable model for recurrence risk prediction is lacking. The aim of this study was to develop and internally validate an integrated predictive model for post-surgical recurrence of pheochromocytoma.Methods: The present research retrospectively enrolled 177 patients affected by pheochromocytoma and submitted to ...

ea0032p518 | Endocrine tumours and neoplasia | ECE2013

Neuroendocrine tumours (NETs) of lung: new data on atypical carcinoid and large cell neuroendocrine carcinoma from a French-Italian multicentric study

Marciello Francesca , Mercier Olaf , Ferolla Piero , David Planchard , Filosso Pier Luigi , Chapelier Alain , Grimaldi Franco , de Latour Bertrand Richard , Blanco Giusy , Guigay Joel , Monaco Guglielmo , Dartevelle Philippe , Papotti Mauro , Scoazec Jean-Yves , Colao Annamaria , Baudin Eric , Faggiano Antongiulio

Introduction: Natural history of lung neuroendocrine tumours (NETs) and in particular of two histological subtypes, atypical carcinoid (AC) and large cell neuroendocrine carcinoma (LCNEC), is poorly known.Aim of the study was to determine disease-free survival (DFS) and overall survival (OS) of sporadic, resectable, non-metastatic lung AC and LNEC.Patients and methods: This retrospective study involved 116 consecutive patients surg...

ea0014p168 | (1) | ECE2007

Somatostatin receptor immunohistochemistry in neuroendocrine tumors: a proposal of scoring system for clinical characterization and therapy selection

Faggiano Antongiulio , Volante Marco , Pia Brizzi Maria , La Rosa Stefano , Rapa Ida , Ferrero Anna , De Chiara Anna , Righi Luisella , Capella Carlo , De Rosa Gaetano , Dogliotti Luigi , Colao Annamaria , Papotti Mauro

Background: Typing somatostatin receptor (SSTR) expression in neuroendocrine tumors (NETs) is of relevance to target an octreotide-based diagnostic approach and treatment. The expanding use of immunohistochemistry to detect SSTR is to date not paralleled by an accurate methodological setting and standardized interpretation of the results.Objective: A multicentric study was designed to compare SSTR immunohistochemical expression with in vivo scinti...